



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Evaluating the species barrier

Citation for published version:

Manson, J & Diack, A 2016, 'Evaluating the species barrier', *Food Safety*.
<https://doi.org/10.14252/foodsafetyfscj.2016022>

Digital Object Identifier (DOI):

[10.14252/foodsafetyfscj.2016022](https://doi.org/10.14252/foodsafetyfscj.2016022)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Food Safety

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Evaluating the Species Barrier

Jean C. Manson and Abigail B. Diack

Neurobiology Division, The Roslin Institute and R(D)SVS, University of Edinburgh, Easter Bush, UK

A Transmissible Spongiform Encephalopathy (TSE) agent from one species generally transmits poorly to a new species, a phenomenon known as the species barrier. However once in the new species it generally but not always adapts and then more readily transmits within the new host. No single test is available to determine accurately the ability of a prion strain to transmit between species. Evaluating the species barrier for any prion strain has to take into consideration as much information as can be gathered for that strain from surveillance and research. The interactions of the agent with a particular host can be measured by *in vivo* and *in vitro* methods and assessing the species barrier needs to make full use of all the tools available. This review will identify the important considerations that need to be made when evaluating the species barrier.

Key words: Prion transmission, PrP, Species barrier, Transgenic models, Transmissible Spongiform Encephalopathies (TSE)

Surveillance

It is important for evaluating risk to animal and human health to be aware of the prion strains that are present within a species and to have a means of detecting novel forms of emerging diseases. Surveillance remains important in determining the extent of prion infection within a species. Animal surveillance in Europe following the outbreak of Bovine Spongiform Encephalopathy (BSE) has determined the extent of the problem and been important for monitoring the decline in BSE following the implementation of the feed bans^{1,2}. Moreover animal surveillance in cattle, sheep and goats has allowed the detection of atypical forms of both BSE and scrapie^{3,4}. Surveillance has mapped the spread of Chronic Wasting Disease (CWD) from the west to the east of the USA and its spread into Canada⁵. Recent surveillance in Norway has identified the first known cases of CWD in Europe^{6,7}. Surveillance in humans has allowed the identification of variant Creutzfeldt-Jakob Disease (vCJD)⁸, has assessed variations in sporadic CJD (sCJD) numbers between countries⁹ and identified a new form of human prion disease namely Variably Protease-Sensitive Prionopathy (VPSP)¹⁰. Ongoing surveillance is required to identify further cases of human prion disease that may occur in different genetic backgrounds, in “at risk” groups or in which diagnosis may be difficult due to confounding factors such as age or other neurodegenerative diseases.

Received: 8 July 2016; Accepted: 11 October 2016; Published online: 7 December 2016

Corresponding author: Prof. Jean Manson, Neurobiology Division, The Roslin Institute and R(D)SVS, University of Edinburgh, Easter Bush, UK (jean.manson@roslin.ed.ac.uk)

The contents of this article reflect solely the view of the author(s).

Conflict of interest statement: The authors had no conflicts of interest to declare in this article.

This paper was presented at the Animal Prion Diseases Workshop “Updated Diagnosis and Epidemiology of Animal Prion Diseases for Food Safety and Security” supported by the OECD Co-operative Research Programme.

Abbreviations: BSE: Bovine Spongiform Encephalopathy; CNS: central nervous system; CWD: Chronic Wasting Disease; PMCA: protein misfolding cyclic amplification; RTQuIC: real time quaking induced conversion; sCJD: sporadic Creutzfeldt-Jakob Disease; TSE: Transmissible Spongiform Encephalopathy; vCJD: variant Creutzfeldt-Jakob Disease; VPSP: Variably Protease-Sensitive Prionopathy




Fig. 1. Incubation period rankings can be a useful tool in assessing TSE strains. Examples of incubation periods from primary passage of experimental sheep BSE, FSE, BSE, vCJD and scrapie in three lines of wild type mice. Abbreviations: BSE, Bovine Spongiform Encephalopathy; FSE, Feline Spongiform Encephalopathy; vCJD, variant Creutzfeldt-Jakob disease.

Strain Identification

Once a new form of disease has been identified it has to be established if this is indeed a new disease or one that has been present for some time. It is also important to establish whether there is any connection between the “new” strain and those already present in the field. Retrospective analysis of atypical scrapie has suggested that this is indeed not a new disease but has been detected in tissue from the 1970’s and has most likely come to light through the extensive European animal surveillance programme¹¹⁾. Similarly within human prion disease the recently identified VPSPr has now been shown to be present in much earlier cases suggesting it was indeed a previously unrecognised prion disease¹²⁾.

Strains can be characterized by both *in vitro* and *in vivo* techniques but it is important to recognize that *in vitro* techniques alone are not sufficient for strain identification. *In vivo* strain identification is undertaken using a validated panel of either wild type or transgenic mice. Following inoculation a number of criteria are measured: the incubation time of disease, the vacuolar pathology and the PrP deposition in the brain at the end point of disease. The importance of the validated panel of mice is that one criteria for assessing strain is the order in which each strain of mice succumbs to disease, namely the ranking of incubation times; this provides important information for assessing the similarity and differences between strains (**Fig. 1**)¹³⁾. Full characterisation of a strain may require a number of sub-passages to overcome the species barrier and to allow stabilization of the strain.

Wild type mouse panels have proven invaluable in identifying the BSE strain and establishing the range of susceptible hosts, i.e. humans, cats, exotic ungulates and primates¹³⁾. They have also determined that a single BSE/vCJD strain is responsible for vCJD cases worldwide¹⁴⁾ and provide a platform for further strain discrimination. *In vivo* strain typing using a variety of models has also identified a number of different strains of scrapie in the field^{15,16)}, and the probability of multiple strains of CWD^{17–19)}. A similar approach can be taken with panels of mice expressing the human *PRNP* gene. These have proven useful for strain typing human prion agents, identifying new diseases and assessing susceptibility to a particular agent of the different human host genotypes, in particular the *PRNP* codon 129 genotype. Using panels of gene-targeted transgenic mice in which the human *PRNP* gene has replaced the murine gene four strains of sCJD have been defined²⁰⁾; VPSPr has been shown to be a unique prion strain²¹⁾ and assessment of vCJD infectivity and susceptibility risks has been undertaken^{22,23)}.

There is a multiplicity of models of transgenic mice with *Prnp* genes carrying different mutations and from different species. The transgenic mice range from multiple copies of *Prnp* genes inserted at random into the genome to transgenic mice produced by gene targeting replacing the endogenous murine *Prnp* gene for an alternative *Prnp* gene^{22,24)}.

The differences between these lines should be considered when using them as tools for strain typing and for assessing the species barrier as the level of the PrP protein might alter the susceptibility of a host to a particular agent. The bank vole has also proven over recent years to be a useful model for strain determination due to its apparently universal permissibility to multiple prion strains^{25–27}). In addition to traditional strain typing criteria, the glycosylation pattern of PrP^{Sc} can also be used as an indicator of a TSE strain as many but not all strains have a unique profile of di, mono and unglycosylated PrP^{Sc}^{28,29}). Different strains may also display different properties when amplified in *in vitro* assay systems such as protein misfolding cyclic amplification (PMCA) and real time quaking induced conversion (RTQuIC). Use of these tools in combination with *in vivo* strain typing can thus provide a powerful method of strain typing.

Host /agent Determinants of Transmission

What defines the ability of a prion strain to transmit within or between species? Some transmit readily within and between species e.g. scrapie and CWD whereas some are very hard to transmit e.g. sCJD and some agents may not transmit at all between individuals. The only known zoonotic prion agent to date is BSE. Understanding the interaction between a host and agent is important in evaluating a species barrier but there are many aspects of this interaction that are not well understood.

While the route and dose of inoculum have some influence over the disease process many other aspects are also important. The ability of an agent to replicate in the periphery and to be transported from the periphery to the central nervous system (CNS) will influence its ability to sustain an infection. One of the most studied aspects of host susceptibility is the *Prnp* genotype of the host and polymorphisms controlling susceptibility and resistance has been elucidated for many species^{30–32}). *Prnp* sequence similarity between host and agent often leads to high susceptibility and differences lead to enhanced resistance but this is not always a good predictor of transmission potential of a particular agent^{33,34}). While some genotypes can provide resistance to one prion strain with a different strain these may be the most susceptible animals. This is particularly well portrayed in sheep with susceptibility and resistance to classical and atypical scrapie where the genotypes leading to resistance with one agent result in susceptibility to the other³⁵). In humans, the codon 129 methionine/valine polymorphism in the human *PRNP* gene has been well studied in at both population level³⁶), in infected humans³²) and in experimental models and has been shown to influence both susceptibility and pathology of disease²²).

Defining Distribution of Infectivity and Routes of Transmission

Possible routes of transmission vary for host agent combinations for example BSE in cattle affects the CNS but shows little involvement of the peripheral tissues. The oral route of transmission through infected meat is therefore considered the most likely manner in which humans acquired vCJD. However when BSE was experimentally transmitted to sheep both CNS and peripheral tissues harbored infectivity³⁷) and BSE transmission to humans in the form of vCJD has shown a very different distribution of infectivity to that of BSE in cattle^{38–41}). This widespread distribution of infectivity in humans has led to transmission of infectivity through blood transfusion which has been demonstrated both experimentally^{42–46}) and in patients with vCJD^{47–49}). Indeed the blood transfusion route appears to be a highly efficient route of prion transmission⁴⁶). CWD in deer appears to have an extensive involvement of peripheral tissues^{50–52}) and therefore there are many routes by which CWD can be transmitted both within and between species. Understanding the distribution of infectivity is therefore an important prerequisite for defining and testing possible routes of transmission.

Adaptation of a Strain within a Host

Once a prion strain has transmitted across a species barrier it generally adapts to its new host and onward transmission within that host becomes more efficient with a greater number of individuals succumbing to disease and shorter incubation times than those observed in the cross species transmission. The ability of a strain to adapt to a new host can in part be modelled in transgenic mice or *in vitro* conversion assays⁵³) (**Fig. 2**). With multiple lines of mice expressing *Prnp* from different species a single transmission from one species to another can give some indication of the likelihood




Fig. 2. Assessing adaptation of a TSE agent *in vivo* and *in vitro*. Serial passage through mice demonstrates higher susceptibilities and strain characteristics can be determined. *In vitro* assays can give a biochemical assessment of transmission and adaptation.

of transmission to that species. To assess the adaptation further transmissions in the same line of mice often demonstrate reductions in incubation times and higher susceptibilities. There is one notable exception to this, however, in vCJD which when passed through gene-targeted transgenic mice expressing the human *PRNP* gene shows no adaptation and indeed with passage the numbers of mice showing pathology decreases. This suggests that humans may not be a good host for vCJD (Diack, personal communication).

Determining Zoonotic Potential of a prion Agent

To date the only known zoonotic prion agent is BSE, which transmitted to humans as vCJD^{54,55}). Other agents such as scrapie have been proposed to be potential zoonotic agents⁵⁶) and concern over the possibility of CWD transmitting to humans has been raised, and the potential for this examined both *in vivo*^{57–59}) and *in vitro*^{60,61}). There is no simple method to assess the zoonotic potential of a prion, but, knowledge of surveillance, strain identification and potential routes of transmission are all important in making such an assessment. Moreover, there are a number of *in vivo* and *in vitro* systems that can provide useful information to aid in assessing the potential zoonotic risk. The *in vitro* conversion assays using material containing a form of human PrP as a template for misfolding can provide information of the ability of human PrP to replicate PrP^{Sc} from other species. Indeed the PMCA assay has been used extensively in this respect and results from this assay have suggested no barrier to transmission between BSE and CWD, but scrapie does not appear to readily amplify human PrP⁶⁰). However *in vitro* amplification systems cannot encompass all the elements that make up the species barrier and *in vivo* studies are also an important component of assessing risk. Non-human primates have been used for assessing zoonotic potential but the most common and widely used tool is transgenic mice expressing the human *PRNP* gene with different polymorphisms at codon 129. Many different lines of these transgenic mice exist with different copy numbers and different sites of integration into the mouse genome. BSE has transmitted to some but not all of these mouse lines^{22,62}) and has been transmitted to macaques^{63,64}). Scrapie has also been shown to transmit to mice overexpressing the human PrP gene⁵⁶) and has also been demonstrated to transmit to squirrel monkeys and a cynomolgus macaque^{65,66}). Conflicting evidence exists for the transmission of CWD to transgenic mice expressing the human *PRNP* gene and it has been shown to transmit to squirrel monkeys but not macaques^{67,68}). These results therefore pose a

Table 1. Assessing zoonotic potential of TSE agents

		BSE	Scrapie	CWD	
Overexpressing human PrP transgenic mice	+	+ [62, 69]	+ [56]	+ [70]	-
Gene targeted human PrP transgenic mice	+	– [22]	ND	– [57]	-
Transmission to primates	+	+ [63, 64]	+ [65]	+ [66, 71]	-
<i>In vitro</i> conversion assays using humanised substrate	+	+ [60, 61]	– [60]	+ [60]	-
Likelihood of zoonotic transmission	Likely	Yes	?	?	Unlikely

There are a number of different ways in which to assess zoonotic potential. Using a combination of evidence from both surveillance and research using *in vivo* and *in vitro* studies gives the best indication of the likelihood of zoonotic transmission. As shown in this table, if all studies give positive (+) results this could be taken as an indication that the risk of zoonotic transmission is high or likely. In contrast, all negative (–) results would indicate that the risk of zoonotic transmission is low or unlikely. Abbreviations: BSE, Bovine Spongiform Encephalopathy; CWD, Chronic Wasting Disease; ND, not done

dilemma since all three agents show positivity in at least two assay systems, which, while not proof that transmission to humans will occur makes it difficult to rule out the possibility of zoonotic transmission.

Summary

The many elements that make up the species barrier are still not fully understood. However, there are many tools within research to examine the possibility of transmission of an agent within and between species. While *in vivo* studies remain an important and vital tool in this assessment, the more recently developed *in vitro* assay systems provide important rapid additional information on the replication ability of the agent with different host species and genotypes with those species. A combination of both surveillance and strain typing can assist in the identification of new strains and compare new strains with old strains. Both *in vivo* and *in vitro* studies allow an assessment of the transmission potential to different species and the influence of the host genotype on host susceptibility. The potential for zoonotic transmission can most fully be assessed using all the tools available and by taking all the evidence from both surveillance and research studies into account (**Table 1**).

References

1. Animal and Plant Health Agency and Department for Environment F.R.A. Guidance note on feed controls in the transmissible spongiform encephalopathies regulations. [cited 2016; Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/398007/TSE-feed-controls.pdf.
2. European Food Safety Authority. [cited 2016; Available from: <https://www.efsa.europa.eu/>.
3. Casalone C, Zanusso G, Acutis P, et al. Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease. *Proc Natl Acad Sci U S A*. 2004; **101**: 3065–3070. [Medline]
4. Benestad SL, Sarradin P, Thu B, Schönheit J, Tranulis MA, Bratberg B. Cases of scrapie with unusual features in Norway and designation of a new type, Nor98. *Vet Rec*. 2003; **153**: 202–208. [Medline]
5. Centers for Disease Control and Prevention. Chronic Wasting Disease (CWD). [cited 2016; Available from: <http://www.cdc.gov/prions/cwd/>.
6. Norwegian Veterinary Institute. Detection of Chronic Wasting Disease in two Norwegian moose. 15/06/2016 Available from: <http://www.vetinst.no/eng/Highlights/Detection-of-Chronic-Wasting-Disease-in-two-Norwegian-moose>.
7. Norwegian Veterinary Institute. The first detection of Chronic Wasting Disease (CWD) in Europe. 19/04/2016; Available from: <http://www.vetinst.no/eng/Highlights/The-first-detection-of-Chronic-Wasting-Disease-CWD-in-Europe>.
8. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. *Lancet*. 1996; **347**: 921–925. [Medline]
9. EuroCJD. Creutzfeldt-Jakob Disease International Surveillance Network. [cited 2016; Available from: <http://www.eurocjd.ed.ac.uk/>.
10. Gambetti P, Dong Z, Yuan J, et al. A novel human disease with abnormal prion protein sensitive to protease. *Ann Neurol*. 2008; **63**: 697–708. [Medline]

11. Chong A, Kennedy I, Goldmann W, et al. Archival search for historical atypical scrapie in sheep reveals evidence for mixed infections. *Journal of General Virology*. 2015; **96**: 3165–3178. [\[Medline\]](#)
12. Head MW, Yull HM, Ritchie DL, et al. Variably protease-sensitive prionopathy in the UK: a retrospective review 1991-2008. *Brain*. 2013; **136**: 1102–1115. [\[Medline\]](#)
13. Bruce ME. TSE strain variation. *Br Med Bull*. 2003; **66**: 99–108. [\[Medline\]](#)
14. Diack AB, Ritchie D, Bishop M, et al. Constant transmission properties of variant Creutzfeldt-Jakob disease in 5 countries. *Emerg Infect Dis*. 2012; **18**: 1574–1579. [\[Medline\]](#)
15. Bruce ME. Scrapie strain variation and mutation. *Br Med Bull*. 1993; **49**: 822–838. [\[Medline\]](#)
16. Bruce ME, Boyle A, Cousens S, et al. Strain characterization of natural sheep scrapie and comparison with BSE. *Journal of General Virology*. 2002; **83**: 695–704. [\[Medline\]](#)
17. Angers RC, Kang HE, Napier D, et al. Prion strain mutation determined by prion protein conformational compatibility and primary structure. *Science*. 2010; **328**: 1154–1158. [\[Medline\]](#)
18. Crowell J, Hughson A, Caughey B, Bessen RA. Host Determinants of Prion Strain Diversity Independent of Prion Protein Genotype. *Journal of Virology*. 2015; **89**: 10427–10441. [\[Medline\]](#)
19. Perrott MR, Sigurdson CJ, Mason GL, Hoover EA. Evidence for distinct chronic wasting disease (CWD) strains in experimental CWD in ferrets. *J Gen Virol*. 2012; **93**: 212–221. [\[Medline\]](#)
20. Bishop MT, Will RG, Manson JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. *Proc Natl Acad Sci U S A*. 2010; **107**: 12005–12010. [\[Medline\]](#)
21. Diack AB, Ritchie DL, Peden AH, et al. Variably protease-sensitive prionopathy, a unique prion variant with inefficient transmission properties. *Emerg Infect Dis*. 2014; **20**: 1969–1979. [\[Medline\]](#)
22. Bishop MT, Hart P, Aitchison L, et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. *Lancet Neurol*. 2006; **5**: 393–398. [\[Medline\]](#)
23. Bishop MT, Diack AB, Ritchie DL, Ironside JW, Will RG, Manson JC. Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease. *Brain*. 2013; **136**: 1139–1145. [\[Medline\]](#)
24. Moore RC, Hope J, McBride PA, et al. Mice with gene targeted prion protein alterations show that Prnp, Sinc and Prni are congruent. *Nat Genet*. 1998; **18**: 118–125. [\[Medline\]](#)
25. Di Bari MA, Chianini F, Vaccari G, et al. The bank vole (*Myodes glareolus*) as a sensitive bioassay for sheep scrapie. *J Gen Virol*. 2008; **89**: 2975–2985. [\[Medline\]](#)
26. Di Bari MA, Nonno R, Castilla J, et al. Chronic wasting disease in bank voles: characterisation of the shortest incubation time model for prion diseases. *PLoS Pathog*. 2013; **9**: e1003219. [\[Medline\]](#)
27. Nonno R, Di Bari MA, Cardone F, et al. Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles. *PLoS Pathog*. 2006; **2**: e12. [\[Medline\]](#)
28. Parchi P, Castellani R, Capellari S, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. *Annals of Neurology*. 1996; **39**: 767–778. [\[Medline\]](#)
29. van Keulen LJM, Langeveld JPM, Dolstra CH, Jacobs J, Bossers A, van Zijderveld FG. TSE strain differentiation in mice by immunohistochemical PrP^{Sc} profiles and triplex Western blot. *Neuropathology and Applied Neurobiology*. 2015; **41**: 756–779. [\[Medline\]](#)
30. Goldmann W. PrP genetics in ruminant transmissible spongiform encephalopathies. *Vet Res*. 2008; **39**: 30. [\[Medline\]](#)
31. Robinson SJ, Samuel MD, O'Rourke KI, Johnson CJ. The role of genetics in chronic wasting disease of North American cervids. *Prion*. 2012; **6**: 153–162. [\[Medline\]](#)
32. Kobayashi A, Teruya K, Matsuura Y, et al. The influence of PRNP polymorphisms on human prion disease susceptibility: an update. *Acta Neuropathologica*. 2015; **130**: 159–170. [\[Medline\]](#)
33. Barron RM, Thomson V, Jamieson E, et al. Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation time across three species barriers. *EMBO J*. 2001; **20**: 5070–5078. [\[Medline\]](#)
34. Manson JC, Jamieson E, Baybutt H, et al. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. *Embo J*. 1999; **18**: 6855–6864. [\[Medline\]](#)
35. Saunders GC, Cawthraw S, Mountjoy SJ, Hope J, Windl O. PrP genotypes of atypical scrapie cases in Great Britain. *Journal of General Virology*. 2006; **87**: 3141–3149. [\[Medline\]](#)
36. Nurmi MH, Bishop M, Strain L, et al. The normal population distribution of PRNP codon 129 polymorphism. *Acta Neurol Scand*. 2003; **108**: 374–378. [\[Medline\]](#)
37. McGovern G, Martin S, Jeffrey M, et al. Influence of breed and genotype on the onset and distribution of infectivity and disease-associated prion protein in sheep following oral infection with the bovine spongiform encephalopathy agent. *Journal of Comparative Pathology*. 2015; **152**: 28–40. [\[Medline\]](#)
38. Rubenstein R, Chang B. Re-assessment of PrP^{Sc} distribution in sporadic and variant CJD. *PLoS ONE*. 2013; **8**: e66352. [\[Medline\]](#)
39. Wadsworth JDF, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. *The Lancet*. 2001; **358**: 171–180. [\[Medline\]](#)
40. Ramasamy I, Law M, Collins S, Brooke F. Organ distribution of prion proteins in variant Creutzfeldt-Jakob disease. *The Lancet Infectious Diseases*. 2003; **3**: 214–222. [\[Medline\]](#)
41. Franz M, Eiden M, Balkema-Buschmann A, et al. Detection of PrP^{Sc} in peripheral tissues of clinically affected cattle after oral challenge with bovine spongiform encephalopathy. *Journal of General Virology*. 2012; **93**: 2740–2748. [\[Medline\]](#)

42. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. *Lancet*. 2000; **356**: 999–1000. [\[Medline\]](#)
43. Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. *J Gen Virol*. 2002; **83**: 2897–2905. [\[Medline\]](#)
44. Baeten LA, Powers BE, Jewell JE, Spraker TR, Miller MW. A natural case of chronic wasting disease in a free-ranging moose (*Alces alces shirasi*). *J Wildl Dis*. 2007; **43**: 309–314. [\[Medline\]](#)
45. McCutcheon S, Alejo Blanco AR, Houston EF, et al. All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD. *PLoS One*. 2011; **6**: e23169. [\[Medline\]](#)
46. Andréoletti O, Litaize C, Simmons H, et al. Highly efficient prion transmission by blood transfusion. *PLoS Pathog*. 2012; **8**: e1002782. [\[Medline\]](#)
47. Hewitt P. vCJD and blood transfusion in the United Kingdom. *Transfus Clin Biol*. 2006; **13**: 312–316. [\[Medline\]](#)
48. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. *Vox Sang*. 2006; **91**: 348. [\[Medline\]](#)
49. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. *Lancet*. 2004; **364**: 527–529. [\[Medline\]](#)
50. Angers RC, Seward TS, Napier D, et al. Chronic wasting disease prions in elk antler velvet. *Emerg Infect Dis*. 2009; **15**: 696–703. [\[Medline\]](#)
51. Race B, Meade-White K, Race R, Chesebro B. Prion infectivity in fat of deer with chronic wasting disease. *J Virol*. 2009; **83**: 9608–9610. [\[Medline\]](#)
52. Mathiason CK, Powers JG, Dahmes SJ, et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. *Science*. 2006; **314**: 133–136. [\[Medline\]](#)
53. Barria MA, Ironside JW, Head MW. Exploring the zoonotic potential of animal prion diseases: in vivo and in vitro approaches. *Prion*. 2014; **8**: 85–91. [\[Medline\]](#)
54. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. *Nature*. 1997; **389**: 498–501. [\[Medline\]](#)
55. Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. *Nature*. 1997; **389**: 448–450, 526. [\[Medline\]](#)
56. Cassard H, Torres J-M, Lacroux C, et al. Evidence for zoonotic potential of ovine scrapie prions. *Nat Commun*. 2014; **5**: 5821. [\[Medline\]](#)
57. Wilson R, Plinston C, Hunter N, et al. Chronic wasting disease and atypical forms of bovine spongiform encephalopathy and scrapie are not transmissible to mice expressing wild-type levels of human prion protein. *J Gen Virol*. 2012; **93**: 1624–1629. [\[Medline\]](#)
58. Sandberg MK, Al-Doujaily H, Sigurdson CJ, et al. Chronic wasting disease prions are not transmissible to transgenic mice overexpressing human prion protein. *J Gen Virol*. 2010; **91**: 2651–2657. [\[Medline\]](#)
59. Kong Q, Huang S, Zou W, et al. Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models. *J Neurosci*. 2005; **25**: 7944–7949. [\[Medline\]](#)
60. Barria MA, Balachandran A, Morita M, et al. Molecular barriers to zoonotic transmission of prions. *Emerg Infect Dis*. 2014; **20**: 88–97. [\[Medline\]](#)
61. Barria MA, Telling GC, Gambetti P, Mastrianni JA, Soto C. Generation of a new form of human PrP^{Sc} in vitro by interspecies transmission from cervid prions. *J Biol Chem*. 2011; **286**: 7490–7495. [\[Medline\]](#)
62. Padilla D, Béringue V, Espinosa JC, et al. Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. *PLoS Pathog*. 2011; **7**: e1001319. [\[Medline\]](#)
63. Lasmézas CI, Deslys JP, Demaimay R, et al. BSE transmission to macaques. *Nature*. 1996; **381**: 743–744. [\[Medline\]](#)
64. Holznagel E, Yutzy B, Schulz-Schaeffer W, et al. Foodborne transmission of bovine spongiform encephalopathy to nonhuman primates. *Emerging Infectious Diseases*. 2013; **19**: 712–720. [\[Medline\]](#)
65. Gibbs CJ Jr, Amyx HL, Bacote A, Masters CL, Gajdusek DC. Oral transmission of kuru, Creutzfeldt-Jakob disease, and scrapie to nonhuman primates. *Journal of Infectious Diseases*. 1980; **142**: 205–208. [\[Medline\]](#)
66. Comoy EE, Mikol J, Luccantoni-Freire S, et al. Transmission of scrapie prions to primate after an extended silent incubation period. *Scientific Reports*. 2015; **5**: 11573. [\[Medline\]](#)
67. Marsh RF, Kincaid AE, Bessen RA, Bartz JC. Interspecies transmission of chronic wasting disease prions to squirrel monkeys (*Saimiri sciureus*). *J Virol*. 2005; **79**: 13794–13796. [\[Medline\]](#)
68. Race B, Meade-White KD, Miller MW, et al. Susceptibilities of nonhuman primates to chronic wasting disease. *Emerg Infect Dis*. 2009; **15**: 1366–1376. [\[Medline\]](#)
69. Asante EA, Linehan JM, Desbruslais M, et al. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. *EMBO J*. 2002; **21**: 6358–6366. [\[Medline\]](#)
70. Kong Q, Cali I, Qing L, Yuan J, s. Huang, D, Kofskey, N, Maurer, D, Mckenzie, J, Safar, W, Zou, and P. Gambetti, Zoonotic potential of CWD Prions: An update., in *Prion 2016*. 2016: Tokyo.
71. Race B, Meade-White KD, Phillips K, Striebel J, Race R, Chesebro B. Chronic wasting disease agents in nonhuman primates. *Emerg Infect Dis*. 2014; **20**: 833–837. [\[Medline\]](#)